Löw, K.; Sitnilska, V.; Tang, Y.; Lammert, J.Q.; Krohne, T.U.; Altay, L.
Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration. J. Pers. Med. 2025, 15, 189.
https://doi.org/10.3390/jpm15050189
AMA Style
Löw K, Sitnilska V, Tang Y, Lammert JQ, Krohne TU, Altay L.
Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration. Journal of Personalized Medicine. 2025; 15(5):189.
https://doi.org/10.3390/jpm15050189
Chicago/Turabian Style
Löw, Katrin, Vasilena Sitnilska, Yuhe Tang, Jeany Q. Lammert, Tim U. Krohne, and Lebriz Altay.
2025. "Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration" Journal of Personalized Medicine 15, no. 5: 189.
https://doi.org/10.3390/jpm15050189
APA Style
Löw, K., Sitnilska, V., Tang, Y., Lammert, J. Q., Krohne, T. U., & Altay, L.
(2025). Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration. Journal of Personalized Medicine, 15(5), 189.
https://doi.org/10.3390/jpm15050189
